Advertisement

Topics

Flex Pharma begins Phase II trial of FLX-787 for ALS in US

19:00 EDT 2 Aug 2017 | Net Resources International

Flex Pharma has begun a Phase II clinical trial (COMMEND) of FLX-787 in the US to treat patients suffering from motor neuron disease (MND) with a focus on amyotrophic lateral sclerosis (ALS).

Original Article: Flex Pharma begins Phase II trial of FLX-787 for ALS in US

NEXT ARTICLE

More From BioPortfolio on "Flex Pharma begins Phase II trial of FLX-787 for ALS in US"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...